AIBIOS

AIBIOS is a biotechnology company focused on developing new medicines to address unmet healthcare needs, particularly in the fields of immunology and oncology. Founded in 2015 by Akio Sato in Tokyo, Japan, the company operates in both Japan and the United States. AIBIOS combines advanced scientific research with industry expertise to create therapies for serious diseases, aiming to improve the health of individuals and society at large. The company invests heavily in research and development, maintaining a growing pipeline of potential treatments. AIBIOS's business model revolves around the discovery and delivery of transformational medicines, generating revenue through the development and commercialization of these therapies. The company serves patients in need of innovative healthcare solutions, working closely with academic institutions like Hokkaido University to explore new scientific pathways. AIBIOS is committed to sustainability and the co-creation of value, fostering a high-engagement culture that supports employee development and recognizes their contributions. Keywords: biotechnology, immunology, oncology, drug discovery, healthcare, therapies, research, development, sustainability, innovation.